Mouwasat Medical Services Company (4002) Q4 2025 earnings summary

Executive summary

• Revenue grew 12% year-over-year to SAR 3,223 million, with net profit up 27.2% to SAR 822 million, driven by higher patient volumes and expanded specialized services.

• Operating profit reached SAR 880 million, up 21.6% from 2024, with gross profit margin at 42.25%.

• Total assets increased to SAR 5,986 million, and equity rose to SAR 3,921 million, reflecting ongoing investments and retained earnings.

• The company distributed SAR 425 million in dividends for 2025, representing a payout ratio of 21.25%.

• The audit report issued an unqualified opinion, confirming compliance with IFRS and SOCPA standards.

Financial highlights

• Revenue: SAR 3,223 million (+12% YoY); Net profit: SAR 822 million (+27.2% YoY); EPS: SAR 4.11.

• Gross profit: SAR 1,361 million (+10.1% YoY); Operating profit: SAR 880 million (+21.6% YoY).

• Gross margin: 42.25%; Net margin: 25.5%; ROA: 13.7%; ROE: 21%.

• Free cash flow: SAR 750 million; Cash and equivalents: SAR 497 million.

• Total loans increased to SAR 948 million; total liabilities rose 22.3% to SAR 2,065 million.

Outlook and guidance

• Targeting a 10% CAGR in revenue through 2028, supported by new hospital openings and service expansions.

• Plans to commence operations at Yanbu Hospital in Q1 2026 and Jeddah Hospital in Q3 2026.

• Continued focus on digital transformation, AI-powered diagnostics, and telemedicine expansion.

• Strategic investments in robotic surgery, specialized clinics, and workforce development.